APGE · As filed with the SEC
Apogee Therapeutics balance sheet, by fiscal year
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Statement | ||||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 131,549,000 | 141,789,000 | 118,316,000 | 151,890,000 |
| Marketable securities | 598,643,000 | 378,864,000 | 277,143,000 | — |
| Prepaid expenses and other current assets | 11,166,000 | 9,060,000 | 2,950,000 | 165,000 |
| Total current assets | 741,358,000 | 529,713,000 | 398,409,000 | 152,055,000 |
| Long-term marketable securities | 172,730,000 | 210,416,000 | — | — |
| Property and equipment, net | 5,688,000 | 1,959,000 | 377,000 | — |
| Right-of-use asset, net | 8,687,000 | 11,365,000 | 2,217,000 | — |
| Other non-current assets | 8,671,000 | 498,000 | 401,000 | — |
| Total assets | 937,134,000 | 753,951,000 | 401,404,000 | 152,055,000 |
| Liabilities and Stockholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable | 1,221,000 | 1,071,000 | 2,143,000 | 418,000 |
| Lease liability | 3,504,000 | 3,234,000 | 1,101,000 | — |
| Accrued expenses | — | — | 17,314,000 | 9,562,000 |
| Accrued expenses and other current liabilities | 23,181,000 | 24,255,000 | — | — |
| Total current liabilities | 27,906,000 | 28,560,000 | 20,558,000 | 9,980,000 |
| Long-term liabilities: | ||||
| Lease liability, net of current | 5,345,000 | 8,597,000 | 933,000 | — |
| Total liabilities | 33,251,000 | 37,157,000 | 21,491,000 | 9,980,000 |
| Preferred Units | — | — | — | 177,467,000 |
| Series A Preferred Units | — | — | — | 28,971,000 |
| Series B Preferred Units | — | — | — | 148,496,000 |
| Stockholders' equity: | ||||
| Common Units; no units authorized, issued and outstanding at December 31, 2023; 5,000,000 units authorized, issued and outstanding as of December 31, 2022 | — | — | — | 2,251,000 |
| Incentive Units; no units authorized, issued and outstanding at December 31, 2023; 12,412,473 units authorized, 9,648,374 issued and 1,625,086 outstanding as of December 31, 2022 | — | — | — | 2,142,000 |
| Common Stock; $0.00001 par value, 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 2025; 400,000,000 authorized, 59,478,725 issued and 58,062,898 outstanding as of December 31, 2024 | 1,000 | 1,000 | — | — |
| Additional paid-in capital | 1,464,561,000 | 1,021,794,000 | 503,354,000 | — |
| Accumulated other comprehensive income | 1,080,000 | 915,000 | 329,000 | — |
| Accumulated deficit | (561,759,000) | (305,916,000) | (123,770,000) | (39,785,000) |
| Total stockholders' equity | 903,883,000 | 716,794,000 | 379,913,000 | (35,392,000) |
| Total liabilities and stockholders' equity | 937,134,000 | 753,951,000 | 401,404,000 | 152,055,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.